Department of Chinese Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
School of Chinese Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Front Immunol. 2022 Nov 2;13:1015142. doi: 10.3389/fimmu.2022.1015142. eCollection 2022.
Diabetic nephropathy (DN) is the most common chronic kidney disease. Accumulation of glucose and metabolites activates resident macrophages in kidneys. Resident macrophages play diverse roles on diabetic kidney injuries by releasing cytokines/chemokines, recruiting peripheral monocytes/macrophages, enhancing renal cell injuries (podocytes, mesangial cells, endothelial cells and tubular epithelial cells), and macrophage-myofibroblast transition. The differentiation and cross-talks of macrophages ultimately result renal inflammation and fibrosis in DN. Emerging evidence shows that targeting macrophages by suppressing macrophage activation/transition, and macrophages-cell interactions may be a promising approach to attenuate DN. In the review, we summarized the diverse roles of macrophages and the cross-talks to other cells in DN, and highlighted the therapeutic potentials by targeting macrophages.
糖尿病肾病(DN)是最常见的慢性肾脏病。葡萄糖和代谢物的积累会激活肾脏中的固有巨噬细胞。固有巨噬细胞通过释放细胞因子/趋化因子、募集外周单核细胞/巨噬细胞、增强肾细胞损伤(足细胞、系膜细胞、内皮细胞和肾小管上皮细胞)以及巨噬细胞-肌成纤维细胞转化,在糖尿病肾病损伤中发挥多种作用。巨噬细胞的分化和相互作用最终导致 DN 的肾脏炎症和纤维化。新出现的证据表明,通过抑制巨噬细胞的激活/转化以及巨噬细胞-细胞相互作用来靶向巨噬细胞可能是减轻 DN 的一种有前途的方法。在综述中,我们总结了巨噬细胞在 DN 中的多种作用以及与其他细胞的相互作用,并强调了通过靶向巨噬细胞的治疗潜力。
Front Immunol. 2022
Int J Clin Exp Pathol. 2014-1-15
Diabetol Metab Syndr. 2025-8-29
Int J Biol Sci. 2025-7-11
Int Urol Nephrol. 2025-8-5
Cardiovasc Toxicol. 2025-7-24
J Diabetes Investig. 2022-2